［1］De Sanjosé S，Diaz M，Castellsagué XC，et al.Worldwide prevalence and genotype distribution of cervical human papillo-mavirus DNA in women with normal cytology：a Meta-analysis［J］.Lancet Infect Dis，2007，7(7)：453-459.
［2］Smith JS，Gilbert PA，Melendy A，et al.Age-specific prevalence of human papillomavirus infection in males：a global review［J］.J Adolesc Health，2011，48(6)：540-542.
［3］Moore RA，Ogilvie G，Fornika D，et al.Prevalence and type distribution of human papillomavirus in 5 000 British Columbia women-implications for vaccination［J］.Cancer Causes Control，2009，20(8)：1387-1396.
［4］Severini A，Jiang Y，Brassard P，et al.Type-specific prevalence of human papillomavirus in women screened forcervical cancer in Labrador，Canada［J］.Int J Circumpolar Health，2013，72：6.
［5］Quinn S，Goldman RD.Human papillomavirus vaccination for boys［J］.Can Fam Physician，2015，61：43-46.
［6］Future II Study Group.Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions［J］.N Engl J Med，2007，356(19)：1915-1927.
［7］Baldur-Felskov B，Dehlendorff C，Munk C，et al.Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women［J］.J Natl Cancer Inst，2014，106(3)：djt460.
［8］Giuliano AR，Palefsky JM，Goldstone S，et al.Efficacy of quadrivalent HPV vaccine against HPV infections and diseasein males［J］.N Engl J Med，2011，364(5)：401-411.
［9］Read TR，Hocking JS，Chen MY，et al.Thenear disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme［J］.Sex Transm Infect，2011，87(7)：544-547.
［10］Powell SE，Hariri S，Steinau M，et al.Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions［J］.Vaccine，2012，31(1)：109-113.
［11］Tabrizi SN，Brotherton JM，Kaldor JM，et al.Fall in human papillomavirus prevalence following a national vaccination program［J］.J Infect Dis，2012，206(11)：1645-1651.
［12］Crowe E，Pandeya N，Brotherton JM，et al.Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities：case-control study nested within a population based screening programme in Australia［J］.BMJ，2014，348：g1458.
［13］Joura EA，Giuliano AR，Iversen OE，et al.A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women［J］.N Engl J Med，2015，372(8)：711-723.
［14］Joura EA，Ault KA，Bosch FX，et al.Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease［J］.Cancer Epidemiol Biomarkers Prev，2014，23(10)：1997-2008.
［15］Serrano B，Alemany L，Tous S，et al.Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease［J］.Infect Agent Cancer，2012，7(1)：38.
［16］Saraiya M，Unger ER，Thompson TD，et al.US assessment of HPV types in cancers：implications for current and 9-valent HPV vaccines［J］.J Natl Cancer Inst，2015，107(6)：86.
［17］Bresse X，Goergen C，Prager B，et al.Universal vaccination with the quadrivalent HPV vaccine in Austria：impact on virus circulation，public health and cost-effectiveness analysis［J］.Expert Rev Pharmacoecon Outcomes Res，2014，14：269-281.
［18］Vesikari T，Brodszki N，van Damme P，et al.A randomized，double-blind，phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil in 9-15-year-old girls［J］.Pediatr Infect Dis J，2015，34(9)：992-998.
［19］Castellsagué X，Giuliano AR，Goldstone S，et al.Immunogenicity and safety of the 9-valent HPV vaccine in men［J］.Vaccine，2015，33(48)：6892-6901.
［20］Van Damme P，Olsson SE，Block S，et al.Immunogenicity and safety of a 9-valent HPV vaccine［J］.Pediatrics，2015，136(1)：e28-e39.
［21］Schilling A，Parra MM，Gutierrez M，et al.Coadministration of a 9-valent human papillomavirus vaccine with meningo-coccal and Tdap vaccines［J］.Pediatrics，2015，136(3)：e563-e572.
［22］Petrosky E，Bocchini JA Jr，Hariri S，et al.Use of 9-val ent human papillomavirus (HPV) vaccine：updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices［J］.MMWR Morb Mortal Wkly Rep，2015，64(11)：300-304.